Monoclonal antibody · Antagonist of Oncostatin M receptor (OSMR) · developed by Genentech
Vixarelimab is an antibody that is studied in chronic pruritus and inflammatory skin conditions, including prurigo nodularis, chronic idiopathic urticaria, lichen planus and plaque psoriasis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03858634 | Phase 2 | Chronic Idiopathic Urticaria | Completed | KNSA |
| NCT03816891 | Phase 2 | Prurigo Nodularis | Completed | KNSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Idiopathic PruritusChronic Idiopathic UrticariaLichen PlanusLichen Simplex ChronicusPlaque PsoriasisPrurigo NodularisPruritis